NR3C2 and Sjogren syndrome: As pathogenic fibrosis and inflammation are thought to be closely linked to the development of the sicca syndrome in oGVHD [22], RAAS and mineralocorticoid receptor blockade present novel therapeutic approaches in managing this complex disease.